Published in J Soc Biol on January 01, 2004
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem (2003) 2.84
Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat Med (2002) 2.46
Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis. J Immunol (2003) 2.22
Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One (2011) 1.60
Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. J Immunol (2008) 1.53
The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood (2010) 1.52
Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. Cell Host Microbe (2008) 1.50
A plant-derived morphinan as a novel lead compound active against malaria liver stages. PLoS Med (2006) 1.49
Plasmodium falciparum--infected erythrocyte adhesion induces caspase activation and apoptosis in human endothelial cells. J Infect Dis (2003) 1.44
Rapid species diagnosis for invasive candidiasis using mass spectrometry. PLoS One (2010) 1.44
Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. PLoS One (2007) 1.41
Helminth infections are associated with protection from cerebral malaria and increased nitrogen derivatives concentrations in Thailand. Am J Trop Med Hyg (2002) 1.31
MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole. Proteomics (2009) 1.26
Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One (2008) 1.25
Expression of human CD81 differently affects host cell susceptibility to malaria sporozoites depending on the Plasmodium species. Cell Microbiol (2006) 1.25
Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. Int J Parasitol (2007) 1.24
Cholesterol contributes to the organization of tetraspanin-enriched microdomains and to CD81-dependent infection by malaria sporozoites. J Cell Sci (2006) 1.23
Scavenger receptor BI boosts hepatocyte permissiveness to Plasmodium infection. Cell Host Microbe (2008) 1.20
Temperature shift and host cell contact up-regulate sporozoite expression of Plasmodium falciparum genes involved in hepatocyte infection. PLoS Pathog (2008) 1.19
Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening. J Antimicrob Chemother (2006) 1.18
Selection of a trioxaquine as an antimalarial drug candidate. Proc Natl Acad Sci U S A (2008) 1.18
In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp. Antimicrob Agents Chemother (2003) 1.16
Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice. J Immunol (2007) 1.14
Inhibitory effect of TNF-α on malaria pre-erythrocytic stage development: influence of host hepatocyte/parasite combinations. PLoS One (2011) 1.12
Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine (2012) 1.11
Decreased hemoglobin concentrations, hyperparasitemia, and severe malaria are associated with increased Plasmodium falciparum gametocyte carriage. J Parasitol (2002) 1.10
Blood-brain barrier breakdown during cerebral malaria: suicide or murder? Thromb Haemost (2005) 1.09
New approach for high-throughput screening of drug activity on Plasmodium liver stages. Antimicrob Agents Chemother (2006) 1.08
Rho kinase inhibition in severe malaria: thwarting parasite-induced collateral damage to endothelia. J Infect Dis (2008) 1.06
Alternative invasion pathways for Plasmodium berghei sporozoites. Int J Parasitol (2006) 1.06
The N'-terminal domain of glyceraldehyde-3-phosphate dehydrogenase of the apicomplexan Plasmodium falciparum mediates GTPase Rab2-dependent recruitment to membranes. Biol Chem (2003) 1.05
Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain. PLoS Pathog (2008) 1.05
Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. FASEB J (2014) 1.04
Transfusion-transmitted malaria. Intensive Care Med (2004) 1.04
Pseudallescheria/Scedosporium complex species identification by Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry. Med Mycol (2011) 1.02
Whole-transcriptome analysis of Plasmodium falciparum field isolates: identification of new pathogenicity factors. J Infect Dis (2007) 1.01
New active drugs against liver stages of Plasmodium predicted by molecular topology. Antimicrob Agents Chemother (2008) 1.01
A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PLoS One (2009) 1.01
The Plasmodium sporozoite survives RTS,S vaccination. Trends Parasitol (2005) 0.98
Transient supplementation of superoxide dismutase protects endothelial cells against Plasmodium falciparum-induced oxidative stress. Mol Biochem Parasitol (2006) 0.97
Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle. Parasitol Res (2004) 0.97
Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage. Malar J (2011) 0.96
Induction of the CD23/nitric oxide pathway in endothelial cells downregulates ICAM-1 expression and decreases cytoadherence of Plasmodium falciparum-infected erythrocytes. Cell Microbiol (2004) 0.94
Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem Biol (2007) 0.94
Hepatitis C virus infection may lead to slower emergence of P. falciparum in blood. PLoS One (2011) 0.93
Antioxidant and anti-inflammatory properties of a Cucumis melo LC. extract rich in superoxide dismutase activity. J Ethnopharmacol (2004) 0.93
Intermittent preventive antimalarial treatment to children (IPTc): firebreak or fire trap? Trends Parasitol (2008) 0.93
Differential aiolos expression in human hematopoietic subpopulations. Leuk Res (2009) 0.92
Heptyl prodigiosin, a bacterial metabolite, is antimalarial in vivo and non-mutagenic in vitro. J Nat Toxins (2002) 0.91
Metabolic acidosis induced by Plasmodium falciparum intraerythrocytic stages alters blood-brain barrier integrity. J Cereb Blood Flow Metab (2010) 0.91
Plasmodium falciparum-infected mice: more than a tour de force. Trends Parasitol (2007) 0.91
Potential value of Plasmodium falciparum-associated antigen and antibody detection for screening of blood donors to prevent transfusion-transmitted malaria. Transfusion (2002) 0.91
Malaria sporozoite: migrating for a living. Trends Mol Med (2004) 0.90
IgE mediates killing of intracellular Toxoplasma gondii by human macrophages through CD23-dependent, interleukin-10 sensitive pathway. PLoS One (2011) 0.90
Testing blood donors for Chagas disease in the Paris area, France: first results after 18 months of screening. Transfusion (2009) 0.89
Aspergillus flavus brain abscesses associated with hepatic amebiasis in a non-neutropenic man in Senegal. Am J Trop Med Hyg (2009) 0.89
A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS One (2007) 0.89
Multilocus phylogeny and MALDI-TOF analysis of the plant pathogenic species Alternaria dauci and relatives. Fungal Biol (2012) 0.87
Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA. Eur J Immunol (2013) 0.87
Inhibition of Plasmodium falciparum field isolates-mediated endothelial cell apoptosis by Fasudil: therapeutic implications for severe malaria. PLoS One (2010) 0.86
Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013. Emerg Infect Dis (2015) 0.86
Isolation and antimalarial activity of new morphinan alkaloids on Plasmodium yoelii liver stage. Bioorg Med Chem (2008) 0.85
Skin-draining lymph node priming is sufficient to induce sterile immunity against pre-erythrocytic malaria. EMBO Mol Med (2012) 0.85
Redox-dependent apoptosis in human endothelial cells after adhesion of Plasmodium falciparum-infected erythrocytes. Ann N Y Acad Sci (2003) 0.85
Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. Blood (2010) 0.84
Submicroscopic Plasmodium falciparum infections before and after sulfadoxine-pyrimethamine and artesunate association treatment in Dienga, Southeastern Gabon. Clin Med Res (2006) 0.83
The Ig domain protein CD9P-1 down-regulates CD81 ability to support Plasmodium yoelii infection. J Biol Chem (2009) 0.83
CD23 mediates antimycobacterial activity of human macrophages. Infect Immun (2009) 0.82
Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy. PLoS One (2013) 0.82
Deletion of T cells bearing the V beta8.1 T-cell receptor following mouse mammary tumor virus 7 integration confers resistance to murine cerebral malaria. Infect Immun (2002) 0.82
Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vet Parasitol (2005) 0.82
Laser capture microdissection of Plasmodium falciparum liver stages for mRNA analysis. Mol Biochem Parasitol (2002) 0.82
Antimalarial activity of crambescidin 800 and synthetic analogues against liver and blood stage of Plasmodium sp. J Antibiot (Tokyo) (2006) 0.81
An enhancer-like region regulates hrp3 promoter stage-specific gene expression in the human malaria parasite Plasmodium falciparum. Biochim Biophys Acta (2007) 0.80
Pooling aqueous humor samples: bias in 2D-LC-MS/MS strategy? J Proteome Res (2010) 0.80
Plasmodium falciparum: hrp3 promoter region is associated with stage-specificity and episomal recombination. Exp Parasitol (2007) 0.78
Supplementation with gliadin-combined plant superoxide dismutase extract promotes antioxidant defences and protects against oxidative stress. Phytother Res (2004) 0.78
Cytoadherence and genotype of Plasmodium falciparum strains from symptomatic children in Franceville, southeastern Gabon. Clin Med Res (2007) 0.78
Laser capture microdissection of hepatic stages of the human parasite Plasmodium falciparum for molecular analysis. Methods Mol Biol (2005) 0.77
High levels of immunoglobulin E autoantibody to 14-3-3 epsilon protein correlate with protection against severe Plasmodium falciparum malaria. J Infect Dis (2012) 0.77
A mouse model for Candida glabrata hematogenous disseminated infection starting from the gut: evaluation of strains with different adhesion properties. PLoS One (2013) 0.76
Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria. Nat Commun (2017) 0.75
Drug hypersensitivity syndrome induced by meglumine antimoniate. Am J Trop Med Hyg (2009) 0.75
[CD81: a tetraspanin implicated in Plasmodium infection]. Med Sci (Paris) (2003) 0.75
1,3,5-Triazepane-2,6-diones as structurally diverse and conformationally constrained dipeptide mimetics: identification of malaria liver stage inhibitors from a small pilot library. Chemistry (2006) 0.75
Wheat gliadin promotes the interleukin-4-induced IgE production by normal human peripheral mononuclear cells through a redox-dependent mechanism. Cytokine (2003) 0.75